T78782 |
PROTAC BTK Degrader-6
|
2767204-39-5
|
98%
|
|
PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression ...
|
T79019 |
JNJ-64264681
|
2101524-34-7
|
98%
|
|
JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK). This compound demonstrates favorable p...
|
T79113 |
BTK-IN-25
|
2562351-92-0
|
98%
|
|
BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].
|
T79292 |
PROTAC BTK Degrader-5
|
|
98%
|
|
PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity by n...
|
T79812 |
BTK-IN-27
|
1841502-36-0
|
98%
|
|
BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM. It is...
|
T79841 |
Cinsebrutinib
|
2724962-58-5
|
98%
|
|
Cinsebrutinib, a Bruton's tyrosine kinase inhibitor identified as compound 5-6 in patent WO2021207549, holds potential for research in cancer treatment.
|
T79890 |
DBt-10
|
|
98%
|
|
DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].
|
T82010 |
JDB175
|
2635328-79-7
|
98%
|
|
JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier. It exhibits potent activity agai...
|
T9814 |
JAK3/BTK-IN-1
|
2674036-91-8
|
98%
|
|
JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important target...
|
T15365 |
G-744
|
1346669-54-2
|
98%
|
|
G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthriti...
|
T10240 |
ACP-5862
|
2230757-47-6
|
98%
|
|
ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective ...
|
T12673L |
PF-06250112
|
1609465-89-5
|
98%
|
|
PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase an...
|
T14357 |
Spebrutinib besylate
|
1360053-81-1
|
98%
|
|
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).
|
T9813 |
JAK3/BTK-IN-2
|
2674036-93-0
|
98%
|
|
JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor. JAK3/ BTk-in-2 inhibits both BTK and JAK3, which are two important targets IN autoimmune diseases. JAK3/ BTk-in-2 ...
|
T16853 |
SB-633825
|
956613-01-7
|
98%
|
|
SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, 1...
|
T14956 |
CHMFL-BTK-01
|
2095280-64-9
|
98%
|
|
CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.
|
T16441 |
PCI-33380
|
1022899-36-0
|
98%
|
|
PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
|
T11379 |
GDC-0834
|
1133432-49-1
|
98%
|
|
GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and r...
|
T6217 |
LFM-A13
|
244240-24-2
|
99.9%
|
|
LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and...
|
T14681 |
BMS-935177
|
1231889-53-4
|
99.89%
|
|
BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.
|